All In Biotech

Drug Trial Radar · NCT03716739

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Mar 19, 2019

Primary completion

May 16, 2025

Study completion Jul 16, 2025

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA)
First posted
Oct 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.

Conditions

  • Prostate Cancer

Interventions

  • Testosterone Cypionate 100 MG/MLDrug

    100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.

  • PlaceboDrug

    Placebo administered by intramuscular injection weekly for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Biochemical Recurrence of Prostate CancerTime frame: the 12-week treatment and the 3-month follow-up
  2. Change From Baseline in Overall Sexual Activity, Assessed Using Psychosexual Diary Questionnaire (PDQ) Question 4Time frame: Week 6, Week 12

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins University

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.